ASX Healthcare Share to Benefit from Increased Scale
The recent changes in the Industry regulatory environment will not only simplify licensing but will increase Medicare funding which could enhance service accessibility and financial performance. With strong Industry fundamentals and with significant capex for site expansion IDX emerges as one of the growing companies to invest in
Integral Diagnostics (ASX: IDX)
Integral Diagnostics (ASX: IDX) has reported strong financial performance for the first half of the fiscal year 2025, with notable revenue growth and improved profitability. The company achieved a revenue increase of 7.8% to $249.4 million, supported by Medicare indexation and rising patient volumes. Operating EBITDA grew by 8.2% to $46.8 million, maintaining a margin of 18.8%, while Operating NPAT saw a significant 31.9% increase to $9.8 million. Free cash flow also improved by 22.7% to $29.4 million, reflecting IDX’s strong operational efficiency.
Read More - https://bit.ly/ASX-Stocks